随后，研究人员以1:1:1的比例将患者随机分配到三组：每日两次服用500 mg UDCA、每日两次服用1000 mg UDCA或安慰剂。 02 研究结果显示，治疗第8周时 ...

对此，Shilpa Medicare的董事总经理Vishnukant Bhutada表示：“我们对SEC的批准感到非常高兴，并期待尽快获得市场授权。我们致力于与监管机构紧密合作，尽快将这一创新疗法带给患者，计划在即将到来的财年内在印度上市。” ...

为探究 UDCA 对肥胖、高血压等慢性疾病的影响，相关研究人员开展关于 UDCA 对人体测量指标、血压和炎症影响的研究，发现其可改善 BMI 和 DBP，但会升高 SBP。该研究为临床治疗提供参考，推荐科研读者阅读。 在当今社会，肥胖、高血压和代谢综合征等慢性疾病 ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...